Caixin
Dec 30, 2022 05:28 AM
BUSINESS

China-Developed Covid Pill Matches Paxlovid, Study Shows

The VV116 Covid antiviral pill is co-developed by Junshi Biosciences and Vigonvita Life Science.
The VV116 Covid antiviral pill is co-developed by Junshi Biosciences and Vigonvita Life Science.

A China-developed Covid antiviral pill appeared to be as effective as Pfizer Inc.’s Paxlovid with fewer safety concerns, according to clinical trial results published Wednesday in the prestigious New England Journal of Medicine.

The trial compared 384 patients taking the drug VV116 developed by Chinese drugmakers Junshi Biosciences and Vigonvita Life Science with 387 patients taking Paxlovid. It found that VV116 was not inferior to Paxlovid with respect to the time to sustained clinical recovery. Drugmakers run noninferiority trials to evaluate a drug compared with an established standard treatment.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST